Results 31 to 40 of about 7,581 (239)

Evaluation of in vitro activity of ceftolozane–tazobactam against recent clinical bacterial isolates from Brazil – the EM200 study

Brazilian Journal of Infectious Diseases, 2020
Background: The emergence of antibiotic resistance is increasing and there are few effective antibiotics to treat infections caused by resistant and multidrug resistant bacterial pathogens.
Felipe Francisco Tuon, Juliette Cieslinski, Suellen da Silva Rodrigues, Fernando Brandão Serra, Marina Della-Negra de Paula   +4 more
doaj   +1 more source

Subgroup analysis of phase 2 study of ceftolozane/tazobactam in neonates and young infants with pyelonephritis

Microbiology Spectrum, 2023
Ceftolozane/tazobactam is approved for the treatment of patients from birth to
Emmanuel Roilides, John S. Bradley, Julia Lonchar, Jennifer A. Huntington, Prachi Wickremasingha, Feng-Hsiu Su, Christopher J. Bruno, Matthew G. Johnson   +7 more
doaj   +1 more source

European intensive care physicians’ experience of infections due to antibiotic-resistant bacteria [PDF]

, 2020
Background Antimicrobial resistance (AMR) compromises the treatment of patients with serious infections in intensive care units (ICUs), and intensive care physicians are increasingly facing patients with bacterial infections with limited or no adequate ...
De Waele, Jan, Friggeri, Arnaud, Garnacho-Montero, José, Gustin, Marie Paule, Jean, Astrid, Kohlenberg, Anke, Lepape, Alain, Monnet, Dominique L., Savey, Anne, Vanhems, Philippe   +9 more
core   +2 more sources

Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015–2018

International Journal of Infectious Diseases, 2021
: Objectives: To report on the activity of ceftolozane-tazobactam and comparators against Pseudomonas aeruginosa isolates collected from hospitalized patients with pneumonia in US intensive care units (ICUs) between 2015 and 2018. Activity against all P.
Michael A. Pfaller, Dee Shortridge, Kelly A. Harris, Mark W. Garrison, C. Andrew DeRyke, Daryl D. DePestel, Pamela A. Moise, Helio S. Sader   +7 more
doaj   +1 more source

Successful ceftolozane/tazobactam treatment of chronic pulmonary infection with pan‐resistant Pseudomonas aeruginosa [PDF]

, 2015
The treatment of chronic Pseudomonas aeruginosa infections is challenging, with resistance and antibiogram diversity accumulating during successive therapies.
Andrews, Ashish, Boucher, Chandorkar, Juan, Lepak, Livermore, Shlaes, Turton, VanScoy   +9 more
core   +1 more source

Association of bla_VIM-2, bla_PDC-35, bla_OXA-10, bla_OXA-488 and bla_VEB-9 β-Lactamase Genes with Resistance to Ceftazidime–Avibactam and Ceftolozane–Tazobactam in Multidrug-Resistant Pseudomonas aeruginosa

Antibiotics, 2022
Ceftazidime–avibactam and ceftolozane–tazobactam are approved for the treatment of complicated Gram-negative bacterial infections including multidrug-resistant (MDR) Pseudomonas aeruginosa.
Mazen A. Sid Ahmed, Faisal Ahmad Khan, Hamad Abdel Hadi, Sini Skariah, Ali A. Sultan, Abdul Salam, Abdul Latif Al Khal, Bo Söderquist, Emad Bashir Ibrahim, Ali S. Omrani, Jana Jass   +10 more
doaj   +1 more source

Multi-drug resistant Gram-negative bacteria: antibiotic-resistance and new treatment strategies [PDF]

, 2017
In this editorial, we treat the multi-drug-resistance of microorganisms such as Klebsiella pneumonia (Kp) and Acinetobacter baumanii and the issues concerning the management of these infections.
Angelis, Massimiliano De, Mascellino, Maria Teresa, Oliva, Alessandra   +2 more
core   +1 more source

Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia [PDF]

, 2020
BACKGROUND: Cefiderocol is a novel siderophore cephalosporin, developed for activity against MDR Gram-negative bacilli (MDR-GNB). OBJECTIVES: To assess the in vitro antibacterial activity of cefiderocol against a collection of MDR-GNB clinical ...
Conejo, Mª del Carmen, Delgado Valverde, María Mercedes, Fernández Cuenca, Felipe Manuel, Pascual Hernández, Álvaro, Serrano, Lara   +4 more
core   +1 more source

Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA) [PDF]

, 2016
Intra-abdominal infections (IAI) are an important cause of morbidity and are frequently associated with poor prognosis, particularly in high-risk patients.
A, A, A, A, A, A, A, A, A, A, A, A, A, AA, AC, AH, AJ, AK, AK, AM, AW, B, B, B, B, BJ, C, C, C, C, CA, CA, CE, D, D, D, DG, DP, E, EA, EE, F, F, F, F, FA, FM, FM, G, G, G, G, G, G, G, GA, GP, H, H, H, H, HAS, HE, I, I, I, I, IJ, J, J, JA, JE, JF, JG, JJ, JJ, JL, JR, JR, JR, JV, K, K, K, K, KA, KC, KYY, L, LJ, M, M, M, M, M, M, M, M, M, M, M, M, M, MA, MA, MA, MA, MC, MG, MM, MN, MP, N, N, NT, O, OR, P, P, P, P, PF, PK, R, R, R, R, R, R, R, RB, RG, RM, RR, RR, RS, RV, S, S, S, S, S, S, S, S, S, Sartelli, SJ, SK, SK, SM, SR, SR, SY, T, T, TL, TM, V, V, VG, VN, W, W, W, WL, WR, Y, YF, YH, YR, YS, Z, ZJ   +173 more
core   +16 more sources

Ceftolozane-tazobactam activity against phylogenetically diverse Clostridium difficile strains [PDF]

, 2015
Ceftolozane-tazobactam (C/T) is approved for the treatment of complicated intra-abdominal and urinary tract infections and has varied activity against anaerobic bacteria. Here, we evaluate the activity of C/T against a phylogenetically diverse collection
Burnham, Carey-Ann D, Dubberke, Erik R, Gonzalez, Mark D, Hink, Tiffany, Wallace, Meghan A   +4 more
core   +2 more sources